Compare ANET & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANET | NVO |
|---|---|---|
| Founded | 2004 | 1923 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 238.0B | 199.4B |
| IPO Year | 2014 | 2001 |
| Metric | ANET | NVO |
|---|---|---|
| Price | $200.14 | $43.24 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 17 | 11 |
| Target Price | ★ $175.18 | $51.00 |
| AVG Volume (30 Days) | 4.4M | ★ 8.4M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 3.19% |
| EPS Growth | ★ 23.32 | N/A |
| EPS | ★ 1.75 | N/A |
| Revenue | ★ $9,005,700,000.00 | N/A |
| Revenue This Year | $29.10 | N/A |
| Revenue Next Year | $21.80 | $3.70 |
| P/E Ratio | $112.38 | ★ $13.60 |
| Revenue Growth | ★ 28.60 | N/A |
| 52 Week Low | $114.52 | $35.12 |
| 52 Week High | $214.89 | $64.16 |
| Indicator | ANET | NVO |
|---|---|---|
| Relative Strength Index (RSI) | 53.97 | 33.56 |
| Support Level | $182.05 | $41.05 |
| Resistance Level | $203.40 | $48.15 |
| Average True Range (ATR) | 6.08 | 0.79 |
| MACD | -0.44 | -0.37 |
| Stochastic Oscillator | 61.91 | 1.99 |
Arista Networks is a networking equipment provider that primarily sells Ethernet switches and software to data centers. Its marquee product is its extensible operating system that runs a single image across every single one of its devices. The firm operates as one reportable segment. It has steadily gained market share since its founding in 2004, with a focus on high-speed applications. Arista counts Microsoft and Meta Platforms as its largest customers and derives roughly three-fourths of its sales from North America.
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the world's leading provider of diabetes care products. Based in Denmark, the company manufactures and markets a variety of human and modern insulins for patients with diabetes, as well as injectable and oral GLP-1 therapies, across its obesity and diabetes care segment. Novo also has a rare disease segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.